In vivo anti-influenza virus activity of a zinc finger peptide

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 3, 1997, Pages 687-692

  Judd, Amrit K ^a   Sanchez, Agustin ^b   Bucher, Doris J ^c   Huffman, John H ^d   Bailey, Kevin ^d   Sidwell, Robert W ^d  

^a SynVax   (United States)

^b STANFORD UNIVERSITY   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX PROTEIN; PEPTIDE 6; RIBAVIRIN; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; INFLUENZA VIRUS A; INTRANASAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS PNEUMONIA; VIRUS STRAIN;

EID: 0031035794     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.3.687     Document Type: Article

References (26)

1. Advisory Committee on Immunization Practices (ACIP). 1986. Prevention and control of influenza. Morbid. Mortal. Weekly Rep. 35:317-331.
2. Allen, H., J. McCauley, M. Waterfield, and M. J. Gething. 1980. Influenza virus RNA segment 7 has the coding capacity for two polypeptides. Virology 107:548-551.
3. Anonymous. 1994. Misconceptions persist about influenza treatment. Antivir. Agents Bull. 7(12):360-361.
4. Bucher, D. J., I. G. Kharitonenkov, J. A. Zakomirdin, V. B. Gregoriev, S. M. Klimenko, and J. F. Davis. 1980. Incorporation of influenza virus M-protein into liposomes. J. Virol. 36:586-590.
5. Calnan, J. B., B. Tidor, S. Biancalana, D. Hudson, and A. D. Frankel. 1991. Arginine-mediated RNA recognition: the arginine fork. Science 252:1167-1171.
6. Clemens, K. R., V. Wolf, S. J. McBryant, P. Zhang, X. Liao, P. E. Wright, and J. M. Gottesfeld. 1993. Molecular basis for specific recognition of both RNA and DNA by a zinc finger protein. Science 260:530-536.
7. Consensus Development Conference, NIH. 1980. Amantadine: does it have a role in the prevention and treatment of influenza? A National Institutes of Health Consensus Development Conference. Ann. Intern. Med. 92:256-258.
8. Erickson, B. W., and R. B. Merrifield. 1976. Solid-phase peptide synthesis, p. 255-527. In H. Neurath (ed.), The proteins, vol. II. Academic Press, Inc., New York, N.Y.
9. Hayden, F. G., J. M. Gwaltney, Jr., R. L. Van de Castle, K. F. Adams, and B. Giordani. 1981. Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob. Agents Chemother. 19:226-233.
10. Hayden, F. G., K. M. Cote, and R. G. Douglas, Jr. 1980. Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob. Agents Chemother. 17:865-870.
11. Hayden, F. G., R. B. Belshe, R. D. Clover, A. J. Hay, M. G. Oaks, and W. Soo. 1989. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N. Engl. J. Med. 321:1696-1702.
12. Huffman, J. N., R. W. Sidwell, D. L. Bernard, A. Morrison, M. J. Otto, C. L. Hill, and R. F. Schinazi. Influenza virus-inhibitory effects of a series of germanium-and silicon-centered polyoxometalates. Antivir. Chem. Chemother., in press.
13. Hutchens, T. W., R. W. Nelson, C. M. Li, and T.-T. Yip. 1992. Peptide metal ion interaction in solution: detection by laser desorption time-of-flight mass spectrometry and electrospray ionization mass spectrometry. Biol. Mass Spectrom. 21:151-159.
14. Judd, A. K., et al. Unpublished data.
15. Judd, A. K., A. Sanchez, I. Kharitonenkov, A. Moscona, E. Nasser, and D. J. Bucher. 1992. M-protein peptides of influenza virus: application as antiviral agents, p. 694-696. In J. A. Smith and J. E. Rivier (ed.), Peptides. ESCOM, Leiden, The Netherlands.
16. Nasser, E. H., A. K. Judd, A. Sanchez, D. Anastasiou, and D. J. Bucher. 1996. Antiviral activity of influenza virus M1 zinc finger peptides. J. Virol. 70:8639-8644.
17. Ryan, D. M., J. Ticehurst, M. H. Dempsey, and C. R. Penn. 1994. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob. Agents Chemother. 38:2270-2275.
18. Scholtissek, C., and G. P. Faulkner. 1979. Amantadine-resistant and -sensitive influenza A strains and recombinants. J. Gen. Virol. 44:807-815.
19. Sidwell, R., J. Huffman, J. Gilbert, B. Moscon, G. Pedersen, R. Burger, and R. Warren. 1992. Utilization of pulse oximetry for the study of the inhibitory effects of antiviral agents on influenza virus in mice. Antimicrob. Agents Chemother. 36:473-476.
20. Sidwell, R. W., J. H. Huffman, G. P. Khare, L. B. Allen, J. T. Witkowski, and R. K. Robins. 1972. Broad-spectrum antiviral activity of Virazole: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705-706.
21. Wakefield, S. L., and G. G. Brownlee. 1989. RNA binding activity of influenza virus matrix protein. Virus Res. 35(Suppl. 2):66.
22. Winter, G., and S. Fields. 1980. Cloning of influenza DNA into M13: the sequence of the RNA segment encoding the A/PR/8/34 matrix protein. Nucleic Acids Res. 8:1965-1974.
23. Ye, Z., N. W. Baylor, and R. R. Wagner. 1988. Transcription-inhibition and RNA-hinding domains of influenza A virus matrix protein mapped with anti-idiotypic antibodies and synthetic peptides. J. Virol. 63:3586-3594.
24. Ye, Z., R. Pal, J. W. Fox, and R. R. Wagner. 1987. Functional and antigenic domains of the matrix (M) protein of influenza A virus. J. Virol. 61:239-246.
25. Ye, Z., and R. R. Wagner. 1992. Down regulation of vesicular stomatitis virus transcription by the matrix protein of influenza virus. J. Gen. Virol. 73:743-748.
26. Zvonarjev, A. Y., and Y. Z. Ghendon. 1980. Influence of membrane (M) protein on influenza A virus virion transcriptase activity in vitro and its susceptibility to rimantadine. J. Virol. 33:583-586.